The ability to noninvasively monitor cellular processes at the molecular level has the potential to lead to new ways of diagnosing and characterizing disease, developing effective therapeutics, and monitoring response to these treatments. Robust molecular imaging requires two components: a molecular-specific source of signal (typically provided through a contrast agent) and an imaging system to detect this signal. Ongoing projects in Richards-Kortum's Optical Spectroscopy and Imaging Laboratory include the development cost-effective optical imaging and spectroscopy tools to reduce the incidence and mortality of cancer and infectious disease through early detection at the point-of-care. In collaboration with the UT MD Anderson Cancer Center, the lab has developed novel cellular and molecular imaging technologies to recognize signatures of early neoplastic disease. At the same time, they have developed optically active, targeted nanoparticles and fluorescent dyes to image directly the molecular hallmarks of cancer. Through clinical trials at MD Anderson, Baylor College of Medicine, and Barretos Cancer Hospital in Brazil the lab has optimized these agents and imaging systems, demonstrating that they can detect precancerous lesions and early cancers in the oral cavity and the esophagus with high sensitivity and specificity.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.